US EditionATTENTION NASDAQ: RCKT INVESTORS: Contact Berger Montague About a Rocket Pharmaceuticals Class Action Lawsuit
- Berger Montague PC is investigating a securities class action lawsuit against Rocket Pharmaceuticals, Inc. regarding critical safety disclosures related to its RP-A501 gene therapy program.
- The lawsuit claims Rocket Pharmaceuticals misled investors about a protocol change before a serious adverse event and an FDA clinical hold.
- Following the disclosure of a patient death in the trial, Rocket Pharmaceuticals' shares dropped nearly 37%, from $6.27 to $2.33 within four days.
- Investors who bought Rocket Pharmaceuticals securities from February 27 to May 26, 2025, may qualify for recovery, with a lead plaintiff application deadline of August 11, 2025.
Insights by Ground AI
Does this summary seem wrong?
36 Articles
36 Articles
Rutland Herald+33 Reposted by 33 other sources
ATTENTION NASDAQ: RCKT INVESTORS: Contact Berger Montague About a Rocket Pharmaceuticals Class Action Lawsuit
PHILADELPHIA, July 15, 2025 /PRNewswire/ -- Berger Montague PC, a nationally recognized securities litigation firm based in Philadelphia, announces it is investigating a newly filed securities class action lawsuit against Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT) ("Rocket Pharmaceuticals" or the "Company").…
Coverage Details
Total News Sources36
Leaning Left5Leaning Right4Center13Last UpdatedBias Distribution59% Center
Bias Distribution
- 59% of the sources are Center
59% Center
L 23%
C 59%
R 18%
Factuality
To view factuality data please Upgrade to Premium
